Skip to search formSkip to main contentSkip to account menu

PF 3512676

Known as: PF-3512676, PF3512676 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Agatolimod SodiumProMune
CpG 7909

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Phase I dose escalation trial of tremelimumab (CP-675,206) administered in combination with PF-3512676 in patients with melanoma or other advanced cancers
3046 Background: Tremelimumab, a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen 4 (CTLA4), and PF… 
2015
2015
Vaccination with long NY-ESO-1 79-108 peptide and CpG-B leads to robust activation of CD4 and CD8 T cell responses in stage III/IV melanoma patients, and a new HLA-DR7 epitope
Although promising, the combination of long synthetic peptides and CpG-B oligodeoxynucleotides has not yet been tested as cancer… 
2014
2014
Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma
Abscopal effects, systemic tumor regression following localized therapy, are induced by radiation therapy and augmented with… 
2009
2009
PF-3512676 may enhance the clinical activity of taxane/platinum chemotherapy in advanced non-small cell lung cancer
Current first-line therapy for stage IIIB–IV non-small-cell lung cancer (NSCLC) is taxane plus platinum-based chemotherapy. With… 
2008
2008
Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC)
8016 Background: Paclitaxel/carboplatin (PC) is standard first line therapy for patients (pts) with Stage IIIB/IV NSCLC. PF… 
2008
2008
Stimulation du récepteur Toll de type 9 au cours des adénocarcinomes pulmonaires mutés pour K-RAS
Highly Cited
2007
Highly Cited
2007
Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma
Purpose: PF-3512676 (formerly CpG 7909) is a novel Toll-like receptor 9–activating oligonucleotide with single-agent antitumor… 
Highly Cited
2007
Highly Cited
2007
Clinical setbacks for toll-like receptor 9 agonists in cancer
Cancer failures are not deterring interest in toll-like receptor agonists for other high profile indications. 
2006
2006
Autologous tumor cell vaccination with PF-3512676 (CPG 7909) and GM-CSF followed by subcutaneous PF-3512676 and IFN-alpha for patients with metastatic renal cell carcinoma.
2530 Background: Metastatic renal cell carcinoma (RCC) has a poor prognosis with a 5-year survival of less than 10%. Non-specific… 
2006
2006
Preliminary Report on a Phase I/II Study of Intratumoral Injection of PF-3512676 (CpG 7909), a TLR9 Agonist, Combined with Radiation in Recurrent Low-Grade Lymphomas.
Background: Low-grade lymphomas are considered incurable, but they are among the most immune-responsive of all human cancers. CpG… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)